Bio-Techne reports Q2 adjusted EPS 40c, consensus 41c

Reports Q2 revenue $272.6M, consensus $277.53M. “I am pleased with the team’s continued execution in this dynamic operating environment, as we navigated a challenging China landscape and conservatism from a subset of biotech customers, which was partially offset by continued strength in our academic end market,” said Kim Kelderman, president and CEO of Bio-Techne. “Encouragingly, we are seeing initial signs of stabilization in China, and remain confident in the long-term high-growth potential of this geography.”